 Artist: Gil Evans: mp3 download Genre(s): Jazz Gil Evans's discography:  Jazz Masters 23 Year: Tracks: 10 One of the to the highest degree substantial arrangers in jazz history, Gil Evans' three album-length collaborations with Miles Davis (Miles Ahead, Porgy and Bess and Sketches of Spain) ar all considered classics. Evans had a extended and varied life history that sometimes ran analogue to the cornetist. Like Davis, Gil became involved in utilizing electronics in the 1970s and preferable not to face plunk for and hearten the past times. He lED his possess band in California (1933-38) which eventually became the backup mathematical group for Skinnay Ennis; Evans stayed on for a clip as transcriber. He gained recognition for his pretty futurist charts for Claude Thornhill's Orchestra (1941-42 and 1946-48) which took vantage of the ensemble's cool tones, utilised French horns and a tuba as frontline instruments and by 1946 incorporate the influence of union Bureau of Prisons. He met Miles Davis (wHO admired his act upon with Thornhill) during this time and contributed arrangements of "Moonlight Dreams" and "Boplicity" to Davis' "Birth of the Cool" nonet. After a time period in obscureness, Evans wrote for a Helen Merrill session and and so collaborated with Davis on Miles Ahead. In addition to his work with Miles (which too included a 1961 recorded Carnegie Hall concert and the half-album Subdued Nights), Evans recorded several superb and highly original sets as a leader (including Gil Evans and Ten, Young Bottle Old Wine and Peachy Jazz Standards) during the epoch. In the 1960s among the albums he worked on for other artists were famed efforts with Kenny Burrell and Astrud Gilberto. After his possess sessions for Verve during 1963-64, Evans waited until 1969 until recording once more as a loss leader. That year's Blue devils in Orbit was his first successful travail at combining acoustic and electric instruments; it would be followed by dates for Artists House, Atlantic (Svengali) and a far-famed tribute to Jimi Hendrix in 1974. After 1975's In that location Comes a Time (which features among its sidemen David Sanborn), to the highest degree of Evans' recordings were taken from live performances. Starting in 1970 he began playing with his large supporting players on a weekly footing in New York clubs. Filled with such all-star players as George Adams, Lew Soloff, Marvin "Hannibal" Peterson, Chris Hunter, Howard Johnson, Pete Levin, Hiram Bullock, Hamiet Bluiett and Arthur Blythe among others, Evans' later on bands were top-heavy in talent only tended to stray on excessively long. Gil Evans, other than sketching out a framework and contributory his keyboard, seemed to permit the orchestra largely campaign itself, inspiring rather than close guiding the music. There were some worthwhile recordings from the 1980s (when the stripe had a long cosmic string of Monday night gigs at Sweet Basil in New York) merely in general they do non ofttimes live up to their potential difference. Prior to his end, Gil Evans recorded with his "arranger's piano" on duets with Lee Konitz and Steve Lacy and his body |
Sunday, 24 August 2008
Mp3 music: Gil Evans
Thursday, 14 August 2008
Obagi Medical Products Launches SoluCLENZ Rx Gel, The Only Prescription Solubilized Benzoyl Peroxide For Acne
�Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetical and therapeutic skin health systems, proclaimed the launch of SoluCLENZ Rx Gel�, a solubilized benzoyl peroxide (BPO) gelatin for the treatment of acne. SoluCLENZ Rx Gel will be available only by prescription starting in mid-August and will be promoted by Obagi Medical's specialty dermatology sales force.
SoluCLENZ Rx Gel contains 5% solubilized BPO, which enhances the follicular penetration of BPO. Traditional BPO formulations ar poorly soluble and many contain micro and macro instruction crystals that may be too large to participate the follicles and treat acne at the reference. Based on a serial publication of clinical studies conducted over the past several years, Obagi Medical has consistently demonstrated that SoluCLENZ Rx Gel is a novel treatment alternative that provides clinically significant lesion reductions that are like to the leading prescription BPO/antibiotic combination products, without the usage of a topical antibiotic drug.
"At Obagi Medical, we pride ourselves on organism business partners with physicians and delivering innovative skin health products," said Steven Carlson, Chief Executive Officer of Obagi Medical Products. "With the launch of our solubilized BPO applied science as a prescription-only product in the pharmacy channel, we continue to offer more options to our physicians. The launch of SoluCLENZ Rx Gel will help dermatologists not solely meet, only exceed their patients' expectations."
About Solubilized Benzoyl Peroxide
Obagi Medical's proprietary, solubilized BPO, known as SoluZyl Technology, is 1/10,000 the size of it of whatsoever other BPO molecule available, so it can perforate deep into the solution of the follicle and treat acne where it starts. Obagi Medical's solubilized 5% BPO is clinically proven to kill more P. acnes bacteria faster than the leading colloidal gel BPO/antibiotic combination product.
About SoluCLENZ
SoluCLENZ Rx is a 5% solubilized BPO gel that uses proprietary ingredients and is indicated for the treatment of acne.
Of the patients who experient expected signs and symptoms of treatment (erythema, peeling, dryness, burning at the stake and/or stinging) during clinical studies, the majority of cases were mild to moderate, occurred during the early weeks of treatment and decreased or resolved over fourth dimension. Although rare, allergic reactions have been reported with topical benzoyl peroxide therapy.
About Obagi Medical Products, Inc.
Obagi Medical Products develops and commercializes skin health products for the dermatology, formative surgery, and related aesthetic markets. Using its Penetrating Therapeutics� technologies, Obagi Medical's products ar designed to improve incursion of agents across the skin barrier for vulgar and visible skin conditions in grownup skin including chloasma, mask of pregnancy, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm�, 1988; Obagi-C� Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi� Professional-C (a phone line of highly stable vitamin C serums), 2005; Obagi� Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm� optic treatment and Obagi CLENZIderm� M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm� M.D. Systems for normal to dry skin, June 2007; and Obagi ELASTIderm� D�colletage System, January 2008 and SoluCLENZ Rx Gel for the pharmacy channel in August 2008.
hTTP://www.obagi.com
Forward-Looking Statements
There are advanced statements contained herein, which can be identified by the manipulation of advanced terminology such as the words "believes," "expects," "crataegus oxycantha," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions. Such innovative statements involve known and unknown risks, uncertainties and other factors that crataegus laevigata cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, simply are non limited to possibility that our ingress into the pharmacy-dispensed communication channel will be unsuccessful and that few physicians will opt to prescribe pharmacy-dispensed SoluCLENZ Rx Gel, the intense contest our products face and will grimace in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and judicial proceeding that could adversely dissemble the profitability of or our ability to sell our products, the possibility that our products whitethorn cause unwanted side effects and the fact that our ability to commercially distribute our products may be importantly harmed if the regulative environment governance our products changes. A more elaborate discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year over December 31, 2007. These factors should be considered carefully and readers ar cautioned non to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this weigh release is as of the date of this press handout and Obagi Medical Products does non intend to update this information.
Obagi Medical Products, Inc.
More info
SoluCLENZ Rx Gel contains 5% solubilized BPO, which enhances the follicular penetration of BPO. Traditional BPO formulations ar poorly soluble and many contain micro and macro instruction crystals that may be too large to participate the follicles and treat acne at the reference. Based on a serial publication of clinical studies conducted over the past several years, Obagi Medical has consistently demonstrated that SoluCLENZ Rx Gel is a novel treatment alternative that provides clinically significant lesion reductions that are like to the leading prescription BPO/antibiotic combination products, without the usage of a topical antibiotic drug.
"At Obagi Medical, we pride ourselves on organism business partners with physicians and delivering innovative skin health products," said Steven Carlson, Chief Executive Officer of Obagi Medical Products. "With the launch of our solubilized BPO applied science as a prescription-only product in the pharmacy channel, we continue to offer more options to our physicians. The launch of SoluCLENZ Rx Gel will help dermatologists not solely meet, only exceed their patients' expectations."
About Solubilized Benzoyl Peroxide
Obagi Medical's proprietary, solubilized BPO, known as SoluZyl Technology, is 1/10,000 the size of it of whatsoever other BPO molecule available, so it can perforate deep into the solution of the follicle and treat acne where it starts. Obagi Medical's solubilized 5% BPO is clinically proven to kill more P. acnes bacteria faster than the leading colloidal gel BPO/antibiotic combination product.
About SoluCLENZ
SoluCLENZ Rx is a 5% solubilized BPO gel that uses proprietary ingredients and is indicated for the treatment of acne.
Of the patients who experient expected signs and symptoms of treatment (erythema, peeling, dryness, burning at the stake and/or stinging) during clinical studies, the majority of cases were mild to moderate, occurred during the early weeks of treatment and decreased or resolved over fourth dimension. Although rare, allergic reactions have been reported with topical benzoyl peroxide therapy.
About Obagi Medical Products, Inc.
Obagi Medical Products develops and commercializes skin health products for the dermatology, formative surgery, and related aesthetic markets. Using its Penetrating Therapeutics� technologies, Obagi Medical's products ar designed to improve incursion of agents across the skin barrier for vulgar and visible skin conditions in grownup skin including chloasma, mask of pregnancy, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm�, 1988; Obagi-C� Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi� Professional-C (a phone line of highly stable vitamin C serums), 2005; Obagi� Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm� optic treatment and Obagi CLENZIderm� M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm� M.D. Systems for normal to dry skin, June 2007; and Obagi ELASTIderm� D�colletage System, January 2008 and SoluCLENZ Rx Gel for the pharmacy channel in August 2008.
hTTP://www.obagi.com
Forward-Looking Statements
There are advanced statements contained herein, which can be identified by the manipulation of advanced terminology such as the words "believes," "expects," "crataegus oxycantha," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions. Such innovative statements involve known and unknown risks, uncertainties and other factors that crataegus laevigata cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, simply are non limited to possibility that our ingress into the pharmacy-dispensed communication channel will be unsuccessful and that few physicians will opt to prescribe pharmacy-dispensed SoluCLENZ Rx Gel, the intense contest our products face and will grimace in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and judicial proceeding that could adversely dissemble the profitability of or our ability to sell our products, the possibility that our products whitethorn cause unwanted side effects and the fact that our ability to commercially distribute our products may be importantly harmed if the regulative environment governance our products changes. A more elaborate discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year over December 31, 2007. These factors should be considered carefully and readers ar cautioned non to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this weigh release is as of the date of this press handout and Obagi Medical Products does non intend to update this information.
Obagi Medical Products, Inc.
More info
Wednesday, 6 August 2008
Babyshambles drummer announces single release
Babyshambles drummer Adam Ficek � wHO records under the alias Roses, Kings, Castles, has announced inside information of his next solo single.
Ficek will release 'Entroubled' on September 8 on his own label, The Sycamore Club'. The single will be available on seven-inch vinyl and digital download.
Ficek will be gift away 1,000 signed copies of the single to fans to signaling up for the press release at MySpace.com/roseskingscastles.
The star will follow the single with the
Ficek will release 'Entroubled' on September 8 on his own label, The Sycamore Club'. The single will be available on seven-inch vinyl and digital download.
Ficek will be gift away 1,000 signed copies of the single to fans to signaling up for the press release at MySpace.com/roseskingscastles.
The star will follow the single with the
Subscribe to:
Posts (Atom)